“Doctors have had a hit list of transcription factors for decades, but we have lacked a way to target them,” said UChicago chemist Raymond Moellering, the senior author on the study. “This work sets the stage for letting us go directly for any transcription factor. If you ask clinicians what they want in order to treat cancer, it’s a way to inhibit Myc. Using the traditional drugs on transcription factors is like trying to get a foothold on a 50-foot vertical cliff. Right away when we ran the gels, we could see that we had cracked the code for the right configuration.”
Chemical Market has been in the industry since almost 40 years. We owe our success to you and since the last few years things have been crazy for the world at large. The editorial independence has never been more important.
Our articles and press releases come from reliable sources and we keep delivering high impact trustworthy news, reviews and technical articles and reports free from commercial or political influence.
We believe everyone deserves equal access to accurate news and there are many news aggregator sites but we don't participate in those as they have a very broad criteria where not all news articles sites can participate and not all of them are true articles written for the purpose of knowledge but mostly are commercialized. We bring you news and information in the chemical industry and provide vital information to make decisions based on fact and not fiction.
Subscribe our magazine for as little as Rs.50 a month (Rs. 600/yr) or $1 a month ($11.99/yr)
